Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $75.253 million which beat the analyst consensus estimate of $54.294 million by 38.60 percent. This is a 171.02 percent increase over sales of $27.767 million the same period last year.